BioSpace News Archive

Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Dr. Roberto Iacone has been named Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005046/en/ CEO of Alentis Therapeutics, Dr. Roberto Iacone. Copyright Alentis Therapeutics Dr. Iacone is a physician

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020. The schedule for the press release and conference call/webcas

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced a strategic category expansion into condition specific dietary supplements with the launch of CV™ Acute, the first of several products to be launched under its new Immunity product line.

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today significant clinical advances of ZEN-3694, the Company’s lead therapeutic compound being developed for epigenetic combination therapies in multiple oncology indications. “Merck, Pfizer, UCSF and Newsoara now form an impressive list of collaborators involved in our development of ZEN-3694 in epigenetic combination therapy programs. We have made significant progress with ZEN-

CAPS Medical, developer of a highly selective and minimally invasive non-thermal plasma device for cancer treatment, today announced the completion of a $3.5 million Series A financing round.

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8751951-sanofi-earnings-results-q2-2020/ Q2 2020 sales results reflect the strong performance of Dupixent ® more than offset by COVID-19 related negative effects on Vaccines, General Medicines an

Meeting tentatively scheduled for August 25, 2020 The USPTO recently awarded the company a patent for its Cannabis-based Extracts and Topicals for Skin Disorder. OWC engaged Stanley Wunderlich, CEO, Consulting for Strategic Growth1, Ltd. for IR/PR representation

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, announced today that it will report its second quarter 2020 financial results and provide a business update on Tuesday, August 11, 2020 before the open of the U.S. financial markets.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020. Following the announcement, the IVERIC bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. To participate in this conference call, dial 888-220-8451

Omega Therapeutics™, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the completion of an $85 million financing.